Ad Header



The Pulse of the Pharmaceutical Industry

Bristol-Myers to invest in Compugen, collaborate in clinical trials

Written by: | | Dated: Thursday, October 11th, 2018


TEL AVIV (Reuters) – Bristol-Myers Squibb Co and Israel’s Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumors.

The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor Opdivo.

In conjunction with the collaboration, Bristol-Myers Squibb will invest $12 million in Compugen, purchasing 2,424,243 shares – equal to a 4.1 percent stake – at $4.95 each. The investment represents a 33 percent premium over the average closing price on the last 20 trading days and is expected to close on or about Oct. 12.

Compugen will sponsor an ongoing two-part early stage trial, which includes evaluating the combination of COM701 and Opdivo in four tumor types, including non-small cell lung, ovarian, breast and endometrial cancer. The collaboration is also designed to address potential future combinations.

Opdivo, approved in over 60 countries, is designed to harness the body’s immune system to help restore anti-tumor immune response.


Reporting by Tova Cohen; Editing by Steven Scheer


Reuters source:


Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom